Back to top
more

Editas Medicine, Inc. (EDIT)

(Real Time Quote from BATS)

$33.55 USD

33.55
474,874

-1.55 (-4.42%)

Updated Jun 16, 2021 02:25 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.41%
2Buy19.02%
3Hold10.72%
4Sell6.46%
5Strong Sell3.06%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 15% (213 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Zacks News

CRISPR (CRSP) Up on Positive New Gene Therapy CTX001 Data

CRISPR Therapeutics' (CRSP) gene-editing therapy, CTX001, shows consistent and sustained response to treatment in patients with transfusion-dependent beta thalassemia and sickle cell disease.

Why Is Editas (EDIT) Down 2.9% Since Last Earnings Report?

Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Editas (EDIT) Q1 Earnings Miss Estimates, Revenues Beat

Editas (EDIT) reports wider-than-expected loss in the first quarter of 2021 while revenues beat estimates. Pipeline development remains in focus for the company.

Editas Medicine (EDIT) Reports Q1 Loss, Tops Revenue Estimates

Editas (EDIT) delivered earnings and revenue surprises of -13.16% and 2.96%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Neena Mishra headshot

Best Biotech Stocks & ETFs for mRNA, Gene Editing

Here is what you should know about investing in these life changing technologies.

Editas (EDIT) to Report Q1 Earnings: What's in the Cards?

On Editas' (EDIT) first-quarter earnings call, investor focus is expected to be on the company's progress with the development of its lead pipeline candidate - EDIT-101.

Vertex (VRTX) Ups Investment in CRISPR Gene Therapy Partnership

Vertex (VRTX) to lead CRISPR Therapeutics for manufacture and commercialization of gene-editing therapy CTX001 which is being developed for treating SCD and TDT.

Why Is Editas (EDIT) Down 9.6% Since Last Earnings Report?

Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Kevin Cook headshot

Software is the New Gold: Storing Value in the Digital-Crypto Age

Time for the final nail in the gilded sarcophagus of the barbarous relic.

bluebird (BLUE) Up on Updated Findings in LentiGlobin's SCD Study

bluebird (BLUE) gains following the updated findings from the reported case of AML in LentiGlobin for SCD gene therapy program.

Editas (EDIT) Misses on Q4 Earnings, Beats on Revenues

Editas (EDIT) reports wider-than-expected loss in the fourth quarter of 2020 while revenues beat estimates. Pipeline development a key focus for the company.

Analysts Estimate Editas Medicine (EDIT) to Report a Decline in Earnings: What to Look Out for

Editas (EDIT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Editas (EDIT) to Report Q4 Earnings: What's in the Cards?

On Editas' (EDIT) fourth-quarter earnings call, investor focus will be on the company's progress with the development of its CRISPR-based experimental candidate, EDIT-101.

Editas Medicine (EDIT) Outpaces Stock Market Gains: What You Should Know

Editas Medicine (EDIT) closed the most recent trading day at $57.94, moving +1.35% from the previous trading session.

Kevin Cook headshot

GameStop Lessons: Becoming a Savvy Investor with ETFs

As more young investors take up day trading, I have a recipe for long-term wealth creation

Kevin Cook headshot

Bear of the Day: CRISPR Therapeutics (CRSP)

Gene editors got a big boost recently from sickle cell potential and Cathie Wood's thematic investing

Kevin Cook headshot

5 Best ETFs for Young Investors

As more young investors take up day trading, I have an important recipe for long-term wealth creation.

Editas Medicine (EDIT) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Editas Medicine (EDIT) closed at $63.18, marking a +1.64% move from the previous day.

Editas Medicine (EDIT) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Editas Medicine (EDIT) closed at $65.47, marking a -0.44% move from the previous day.

Kevin Cook headshot

Bear of the Day: Illumina (ILMN)

Maker of premier next-gen genomic sequencing technology lowers guidance but shares make new highs

CRISPR (CRSP) Up More Than 80% in Past 3 Months: Here's Why

CRISPR Therapeutics' (CRSP) lead gene-editing candidate CTX001, being developed for treating SCD and TDT, holds potential. It has a strong partner in Vertex.

Editas (EDIT) Up More Than 100% in Past 3 Months: Here's Why

Editas' (EDIT) lead candidate EDIT-101, that employs CRISPR gene editing to treat LCA10, holds potential. The company is also developing EDIT-301 for treating SCD.

Editas Medicine (EDIT) Gains As Market Dips: What You Should Know

Editas Medicine (EDIT) closed at $76.14 in the latest trading session, marking a +0.29% move from the prior day.

Editas (EDIT) Gets FDA Nod to Begin Safety Study on EDIT-301

The FDA clears the initiation of the safety phase of Editas' (EDIT) early-stage study on investigational gene-editing therapy EDIT-301 for treating sickle cell disease. Shares down.

The Zacks Analyst Blog Highlights: Intellia Therapeutics, Editas Medicine, Fate Therapeutic, CRISPR Therapeutics and Vertex Pharmaceuticals

The Zacks Analyst Blog Highlights: Intellia Therapeutics, Editas Medicine, Fate Therapeutic, CRISPR Therapeutics and Vertex Pharmaceuticals